EP. 6: Tackling Secondary Progressive Multiple Sclerosis Early on Benefits Patients in a Number of WaysDecember 4th 2020
Thomas P. Leist, MD, PhD, discusses secondary progressive MS, more specifically how very early control of the disease gives the patient the best chance for long term stability and gives the patient, the best chance of not entering the secondary state.
EP. 7: Biomarkers Used to Detect Secondary Progressive MS Needs Improvement for the Care of PatientsDecember 11th 2020
Thomas P. Leist, MD, PhD, says doctors working with patients diagnosed with SPMS don't necessarily have prognostic biomarkers to detect SPMS. The best prognostic biomarkers they have currently are MRI and potentially neurofilament light. He adds their techniques need to improve in order to harness the full benefit of potentially individualizing care to the most optimal fashion in a given patient.
EP. 10: A Labeling Indication of SPMS Can Treat More PatientsDecember 16th 2020
Fred Lublin, MD, says a new labeling indication of Secondary Progressive Multiple Sclerosis broadens whom you can treat. He adds this will be very helpful to patients because it will treat groups that are progressing slowly without agents of activity.
EP. 11: The Struggle of Making an Effective SPMS Treatment Early onFebruary 7th 2021
Thomas P. Leist, MD, PhD, says one of the things secondary progressive multiple sclerosis professionals struggle with is making the most effective treatment available to patients, very early on, most likely due to financial reasons.